Seretide for obstructive lung disease
- 1 March 2002
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 3 (3) , 341-350
- https://doi.org/10.1517/14656566.3.3.341
Abstract
Seretide® (Advair® [North America], GlaxoSmithKline) is an inhaler combination formulation intended for the maintenance therapy of obstructive airways disease. Seretide was developed and made available initially as three multi-dose, dry powder inhaler formulations delivering 50 μg/puff of the long acting β2agonist salmeterol and either 100, 250 or 500 μg/puff of the inhaled corticosteroid fluticasone propionate. In addition to the initial multi-dose dry powder inhaler system (Diskus® or Accuhaler®), a chlorofluorocarbon (CFC)-free pressurised aerosol formulation has become available. Studied mostly extensively as a maintenance therapy for patients with persistent asthma, the combination inhaler is at least equivalent to its components administered separately and is superior to monotherapy with salmeterol or inhaled corticosteroid in both paediatric and adult populations. The combination has a logical role in the treatment of moderate-to-severe asthma, offering the advantage of increased convenience and po...Keywords
This publication has 33 references indexed in Scilit:
- Effect of salmeterol on patients' adherence to their prescribed refills for inhaled corticosteroidsAnnals of Allergy, Asthma & Immunology, 2000
- The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthmaAnnals of Allergy, Asthma & Immunology, 1999
- EUROSCOP, ISOLDE and the Copenhagen City Lung StudyThorax, 1999
- Dose-Related Response to Inhaled Fluticasone Propionate in Patients with Methacholine-Induced Bronchial Hyperresponsiveness: A Double-Blind, Placebo-Controlled StudyJournal of Asthma, 1998
- Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patientsThorax, 1997
- Dose-Response of Inhaled Drugs in AsthmaClinical Pharmacokinetics, 1997
- Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of actionEuropean Respiratory Journal, 1996
- A 12-Week Dose-Ranging Study of Fluticasone Propionate Powder in the Treatment of AsthmaJournal of Asthma, 1996
- A comparative study in atopic subjects with asthma of the effects of salmeterol and salbutamol on allergen-induced bronchoconstriction, increase in airway reactivity, and increase in urinary leukotriene E4 excretionJournal of Allergy and Clinical Immunology, 1992
- Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol1Journal of Allergy and Clinical Immunology, 1990